Cowen Upgrades Merrimack Pharmaceuticals (MACK) to Outperform

Merrimack Pharmaceuticals (MACK) Surges on Strong Trial Results; JP Morgan PT Hike

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) is up 78% in pre-open trade after the company announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU... More

UPDATE: Merrimack Pharmaceuticals (MACK) Price Target Raised to $15 at JPMorgan

(Updated - May 1, 2014 10:03 AM EDT)

JPMorgan maintained an Overweight rating on Merrimack Pharmaceuticals (NASDAQ: MACK) and raised its price target to $15.00 (from $9.00).

Analyst Geoff Meacham said, "Merrimack reported positive top-line data for the phase 3 NAPOLI-1 data of MM-398 in second-line pancreatic cancer (PC). The combination arm of MM-398 + 5FU/LV... More

Merrimack Pharma (MACK) NAPOLI-1 Phase 3 Met Primary Endpoint

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone. The NAPOLI-1 Phase 3 study was conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. The primary log-rank analysis of overall survival was statistically significant (p=0.012) with a corresponding hazard ratio of 0.67. A statistically significant advantage for progression free survival was also observed in the combination arm.

The most common Grade 3... More

Merrimack Pharm (MACK) Posts Mixed Q1 Results

Merrimack Pharm (NASDAQ: MACK) reported Q1 EPS of ($0.27), $0.03 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $13.03 million versus the consensus estimate of $11.93 million.

For earnings history and earnings-related data on Merrimack Pharm (MACK) click here.